Status:
WITHDRAWN
Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
Lead Sponsor:
Pfizer
Conditions:
Hypercholesterolemia
Dyslipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of RN316 in eligible healthy volunteers. RN316 is an investigational drug that is currently being studi...
Eligibility Criteria
Inclusion
- LDL-C must be greater or equal to 130 mg/dl
- BMI must be between 18.5 and 40 kg/m2
Exclusion
- History of cardiovascular or cerebrovascular event during the past year.
- Poorly controlled type 1 or type 2 diabetes mellitus
- Subjects who have taken lipid lowering therapies within the last 3 months of screening.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01163838
Start Date
August 1 2010
End Date
March 1 2011
Last Update
April 23 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.